Glassia®

Understanding Glassia®

Glassia® is an intravenous (IV) therapy used to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic conditionthat can lead to emphysema and lung damage. Glassia® works by increasing levels of alpha1-proteinase inhibitor (A1PI) in the blood, which helps protect lung tissue from damage and slows disease progression. As the first ready-to-use IV therapy for AATD, Glassia® offers a convenient and effective treatment option for patients with this condition.

How Glassia® Works:

• Increases A1PI levels to protect lung tissue from progressive damage
• Slows the progression of emphysema and lung disease in AATD patients
• Provides a ready-to-use IV formulation, reducing preparation time for treatment

FDA Approval:

• Glassia®: Approved on July 1, 2010

For more information, please visit the Glassia® patient website and speak with your healthcare provider to determine if Glassia® is the right treatment option for you.